Endoscopic skull base surgery has created a new era of skull base surgery. With the development of endoscopic skull base surgery technology and the cooperation in-depth among multiple disciplines, endoscopic skull base surgery has gradually expanded from midline skull base to paramidline skull base. In addition to pituitary tumor, meningioma, craniopharyngioma, and other benign lesions, the technology of endoscopic skull base surgery is gradually used in the treatment of malignant lesions, with olfactory neuroblastoma being the most typical. In addition, endoscopic skull base surgery in the treatment of recurrent nasopharyngeal carcinoma, adenoid cystic carcinoma, chordoma, and other malignant lesions also showed obvious advantages. The combination of interventional neuroradiology, surgical revascularization technique, and endoscopic skull base surgical technique further expands the indications of endoscopic skull base surgery, and greatly reduced the risk of internal carotid artery injury. At the same time, the development of radiotherapy, especially the new radiotherapy technologies such as Proton and Carbon-ion radiotherapy, provides a new therapeutic tool for skull base tumors that is insensitive to traditional radiotherapy and has achieved certain clinical curative effect. In addition, immunotherapy represented by anti-PD-1 antibody has shown potential antitumor activity and reliable safety in the fields of mucosal malignant melanoma and recurrent nasopharyngeal carcinoma. Further research is needed to improve the survival rate of the sinonasal and skull base tumors.
The aim of this Research Topic is to bring together high-quality and up-to-date progress in endoscopic surgery for sinonasal and skull base tumors. At the same time, potential clinical value of new radiotherapy technologies, such as Proton and Carbon-ion radiotherapy, in the treatment of certain skull base tumors will also be discussed, in order to provide clinical evidence for multidisciplinary comprehensive treatment of skull base tumors. Therefore, we welcome Original Research, Review, and Clinical Trials focusing on but not limited to the following aspects:
- Endoscopic treatment of pituitary tumor, craniopharyngioma, meningioma, shwannoma.
- Endoscopic surgery or radiotherapy for clival chordoma or chondrosarcoma.
- Endoscopic endonasal clipping of intracranial aneurysms, resecting of intracranial vascular lesions and the treatment of internal carotid artery injury during endoscopic endonasal surgery.
- Comprehensive treatment of olfactory neuroblastoma based on endoscopic skull base surgery.
- Endoscopic surgery and radiotherapy for adenoid cystic carcinoma.
- Endoscopic skull base surgery for recurrent nasopharyngeal carcinoma.
- Endoscopic skull base reconstruction technology.
- Endoscopic surgery or chemoradiotherapy for squamous cell carcinoma of nasal cavity and paranasal sinuses.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Endoscopic skull base surgery has created a new era of skull base surgery. With the development of endoscopic skull base surgery technology and the cooperation in-depth among multiple disciplines, endoscopic skull base surgery has gradually expanded from midline skull base to paramidline skull base. In addition to pituitary tumor, meningioma, craniopharyngioma, and other benign lesions, the technology of endoscopic skull base surgery is gradually used in the treatment of malignant lesions, with olfactory neuroblastoma being the most typical. In addition, endoscopic skull base surgery in the treatment of recurrent nasopharyngeal carcinoma, adenoid cystic carcinoma, chordoma, and other malignant lesions also showed obvious advantages. The combination of interventional neuroradiology, surgical revascularization technique, and endoscopic skull base surgical technique further expands the indications of endoscopic skull base surgery, and greatly reduced the risk of internal carotid artery injury. At the same time, the development of radiotherapy, especially the new radiotherapy technologies such as Proton and Carbon-ion radiotherapy, provides a new therapeutic tool for skull base tumors that is insensitive to traditional radiotherapy and has achieved certain clinical curative effect. In addition, immunotherapy represented by anti-PD-1 antibody has shown potential antitumor activity and reliable safety in the fields of mucosal malignant melanoma and recurrent nasopharyngeal carcinoma. Further research is needed to improve the survival rate of the sinonasal and skull base tumors.
The aim of this Research Topic is to bring together high-quality and up-to-date progress in endoscopic surgery for sinonasal and skull base tumors. At the same time, potential clinical value of new radiotherapy technologies, such as Proton and Carbon-ion radiotherapy, in the treatment of certain skull base tumors will also be discussed, in order to provide clinical evidence for multidisciplinary comprehensive treatment of skull base tumors. Therefore, we welcome Original Research, Review, and Clinical Trials focusing on but not limited to the following aspects:
- Endoscopic treatment of pituitary tumor, craniopharyngioma, meningioma, shwannoma.
- Endoscopic surgery or radiotherapy for clival chordoma or chondrosarcoma.
- Endoscopic endonasal clipping of intracranial aneurysms, resecting of intracranial vascular lesions and the treatment of internal carotid artery injury during endoscopic endonasal surgery.
- Comprehensive treatment of olfactory neuroblastoma based on endoscopic skull base surgery.
- Endoscopic surgery and radiotherapy for adenoid cystic carcinoma.
- Endoscopic skull base surgery for recurrent nasopharyngeal carcinoma.
- Endoscopic skull base reconstruction technology.
- Endoscopic surgery or chemoradiotherapy for squamous cell carcinoma of nasal cavity and paranasal sinuses.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
